- Home
- AGEN vs PEBK Comparison
AGEN vs PEBK Comparison
Compare AGEN & PEBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- PEBK
- Stock Information
- Founded
- AGEN 1994
- PEBK 1912
- Country
- AGEN United States
- PEBK United States
- Employees
- AGEN N/A
- PEBK N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PEBK Major Banks
- Sector
- AGEN Health Care
- PEBK Finance
- Exchange
- AGEN Nasdaq
- PEBK Nasdaq
- Market Cap
- AGEN 142.8M
- PEBK 162.7M
- IPO Year
- AGEN 2000
- PEBK N/A
- Fundamental
- Price
- AGEN $4.25
- PEBK $30.21
- Analyst Decision
- AGEN Buy
- PEBK
- Analyst Count
- AGEN 2
- PEBK 0
- Target Price
- AGEN $14.50
- PEBK N/A
- AVG Volume (30 Days)
- AGEN 431.2K
- PEBK 6.6K
- Earning Date
- AGEN 11-11-2025
- PEBK 10-20-2025
- Dividend Yield
- AGEN N/A
- PEBK 3.15%
- EPS Growth
- AGEN N/A
- PEBK 4.77
- EPS
- AGEN N/A
- PEBK 3.11
- Revenue
- AGEN $101,706,000.00
- PEBK $84,131,000.00
- Revenue This Year
- AGEN $60.49
- PEBK N/A
- Revenue Next Year
- AGEN N/A
- PEBK N/A
- P/E Ratio
- AGEN N/A
- PEBK $9.80
- Revenue Growth
- AGEN N/A
- PEBK 6.23
- 52 Week Low
- AGEN $1.38
- PEBK $23.74
- 52 Week High
- AGEN $7.34
- PEBK $33.90
- Technical
- Relative Strength Index (RSI)
- AGEN 45.64
- PEBK 45.37
- Support Level
- AGEN $3.78
- PEBK $30.32
- Resistance Level
- AGEN $4.38
- PEBK $31.79
- Average True Range (ATR)
- AGEN 0.24
- PEBK 0.39
- MACD
- AGEN 0.00
- PEBK -0.10
- Stochastic Oscillator
- AGEN 47.55
- PEBK 20.01
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.